Perspective Therapeutics (NYSE:CATX) Earns Outperform Rating from Wedbush
Wedbush reiterated their outperform rating on shares of Perspective Therapeutics (NYSE:CATX – Free Report) in a research report report published on Monday morning,RTT News reports. Wedbush currently has a $11.00 price target on the stock. A number of other equities analysts have also commented on the company. Cantor Fitzgerald upgraded Perspective Therapeutics to a “strong-buy” […]
Wedbush reiterated their outperform rating on shares of Perspective Therapeutics (NYSE:CATX – Free Report) in a research report report published on Monday morning,RTT News reports. Wedbush currently has a $11.00 price target on the stock. A number of other equities analysts have also commented on the company. Cantor Fitzgerald upgraded Perspective Therapeutics to a “strong-buy” […]
